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Abstract
Purpose To determine the clinical performance of a blood-based test for clinically significant (CS) prostate cancer (PCa) 
(grade group ≥ 2) intended for use in men with prostate serum antigen levels in the ‘grey zone’ (PSA < 10 ng/ml). The test 
quantifies a previously described 3.4 kb mitochondrial DNA (mtDNA) deletion.
Methods In a first prospective study of an MRI-guided re-biopsy population (n = 126), the 3.4 kb deletion and 18S rRNA 
gene were amplified from plasma. A diagnostic threshold was selected from the coordinates of the receiver operating char-
acteristic curve and tested in a second population of men who were (n = 92) biopsy naïve when the mtDNA deletion was 
assayed and for whom those diagnosed with cancer on initial biopsy were treated with radical prostatectomy.
Results The 3.4 kb deletion was a good predictor of CS PCa in the image-guided re-biopsy population [AUC 0.84, (95% CI 
0.73–0.95)] and the selected threshold corresponded to a sensitivity of 87% [95% CI, 70–96%], specificity of 68% [95% CI, 
47–85%] and negative predictive value (NPV) of 97%. Applying this threshold to the second population showed this deletion 
to be a strong predictor of CS cancer [AUC 0.98, (95% CI 0.94–1.02)], independent of PSA or age [sensitivity 100% (95% 
CI, 93–100%), specificity 90% (95%CI 73–98%) and NPV 100%].
Conclusion The 3.4 kb deletion in plasma is an accurate predictor of CS cancer for men in the PSA ‘grey zone’. Used in 
advance of biopsy for improved patient selection, this deletion may reduce the number of biopsies needed to diagnose CS 
prostate cancers.
Keywords Mitochondrial DNA · Prostate cancer · Multi-parametric magnetic resonance imaging · Plasma · Biomarker · 
DNA deletion · Real-time PCR · Diagnostic accuracy
Introduction
Indication for prostate biopsy due to suspicion of prostate 
cancer is primarily driven by elevated levels of serum pros-
tate-specific antigen (PSA) [1, 2]. While inexpensive and 
accessible, effective use of PSA for screening is limited by 
its low diagnostic accuracy [3]. Further, most PSA measure-
ments are within the PSA ‘grey zone’, < 10 ng/ml where 
accuracy is much lower [4]. Thus, the identification of a 
prostate cancer biomarker that can be measured in blood, 
provided at low cost, is independent of PSA, and accurately 
identifies CS prostate cancers that would benefit from near-
term intervention, is a pressing need.
We and others have previously reported the clinical 
value of a 3.4 kb mitochondrial DNA (mtDNA) deletion 
(Online Resource 1) strongly correlated with the presence 
of prostate cancer and elevated even in normal-appearing 
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prostate cells coexisting with malignant cells—exhibiting 
the concept of field cancerization [5–8]. Using laser cap-
ture micro-dissection, we reported that the quantity of the 
deletion while significantly elevated in malignant prostate 
cells, was not elevated in benign prostate conditions such as 
hyperplasia and inflammation [5]. As a biomarker derived 
from the mitochondrial genome, this deletion has several 
inherent biological traits that confer an advantage over its 
nuclear genome counterparts [9–11]. Briefly, mitochondrial 
genome deletions are heteroplasmic [9] and cellular energy 
production can be maintained even with a significant pro-
portion of mutated mitochondrial genomes [9]. Thus, the 
mutated deleted species can persist in the cell instead of 
being repaired, increasing the window of time for detection. 
The subcellular location of mtDNA within the mitochon-
drial matrix positions it on the front line of cellular stress 
responses such as reactive oxygen species production, thus 
mtDNA mutation events can be an early indicator of the dis-
ease [10]. Mitochondrial alterations can contribute directly 
to tumour cell progression and metastasis, meaning, these 
mutations can be closely entwined with the disease itself 
[12]. Finally, mtDNA outnumber the nuclear genome in each 
cell by hundreds to thousands of copies, translating to robust 
detection in samples with even limited cellularity such as 
blood plasma [11].
Here we have focused on determining the diagnostic accu-
racy of the 3.4 kb mtDNA deletion in its cell-free circulating 
DNA form for men in the PSA ‘grey zone’ (PSA < 10 ng/
ml) to detect CS cancer, defined as grade group 2 or greater 
(Gleason score 7 or greater). In this study, we defined a 
diagnostic threshold in an image-guided re-biopsy popula-
tion and tested its performance in a second population of 
men who were biopsy naïve at the time of blood collection. 
Men diagnosed with prostate cancer in the second popula-
tion were diagnosed on first biopsy and treated with radical 
prostatectomy, thus deletion levels were correlated to final 
surgical pathology.
Methods
Study cohorts
Image‑guided re‑biopsy population
Patients and samples were recruited from prostate cancer 
clinics at the Department of Urology, Cambridge Univer-
sity Hospitals Trust (CUHT), Cambridge UK [Ethics (Ethics 
03/018—NRES Committee East of England, UK)]. All men 
previously had a PSA < 10 ng/ml, at least one prior negative 
prostate biopsy and required re-biopsy because of ongoing 
suspicion of cancer. Blood was collected for testing prior to 
MRI-guided repeat biopsy. All had a mpMRI and proceeded 
to trans-perineal template biopsy regardless of whether a tar-
get lesion was identified or not. Patients underwent mpMRI 
on a 1.5T MR450 or 3T Discovery MR750-HDx system 
(GE Healthcare, USA) with a multi-channel surface phased 
array coil, including standard anatomical and functional 
diffusion-weighted imaging using multiple b-values, as 
previously described [13]. T2W and DWI sequences were 
evaluated and scored using a Likert scale of cancer prob-
ability, based on the prostate imaging reporting and data 
system (PI-RADS) descriptors developed by the European 
Society of Urogenital Radiology (ESUR) [14]. The contours 
of mpMRI defined lesions (Likert 3–5) were drawn on the 
BiopseeTM fusion platform (Medcom, Germany). No lesion 
or Likert 1–3 lesions were considered mpMRI negative for 
this study. 24 sectoral biopsies + 2 from each target area 
using image fusion guidance (where applicable) were taken 
using a previously published standardized template [13]. 
Men without mpMRI lesions (mpMRI negative) had only 
24 sectoral biopsies taken. Biopsy samples were processed 
through a single pathology laboratory and reported by spe-
cialist uropathologists (using ISUP 2005) [15].
First biopsy cohort
Patients and samples were recruited by the Ontario Tumour 
Bank (Toronto, Canada) and Bioreclamation IVT (Westbury, 
New York, USA). All men were biopsy naïve at the time 
of blood collection. For cancer positive cases the inclusion 
criteria were (1) men diagnosed with cancer on first biopsy 
(2) presenting with PSA < 10 ng/ml, (3) plasma collected 
pre-biopsy and (4) treated with a radical prostatectomy with 
final surgical histology available. Age at the time of blood 
collection was recorded as within 5-year intervals, thus for 
analysis, the median value of the interval was used. Biologi-
cal materials were provided by the Ontario Tumour Bank. 
As control (non-cancer) samples were not available from the 
Ontario Tumour Bank, male control samples were obtained 
from Bioreclamation IVT. PSA levels were not available 
for these men, however, at the time of enrolment none had 
a prior diagnosis of prostate cancer and were not in a urolo-
gist’s care due to suspicion of prostate cancer as verified 
during donor screening by Bioreclamation IVT.
Sample handling and processing
Blood samples were collected in K2EDTA and plasma was 
separated by centrifugation and frozen until DNA extraction. 
DNA was isolated from 200 μl plasma using the QIAamp 
96 QIAcubeHT extraction kit (Qiagen, Crawley, UK). The 
18S rRNA gene and 3.4 kb deletion were quantified using 
quantitative polymerase chain reaction. Detailed methods 
and assay performance are provided in Online Resource 2.
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PCR reagent kit–The PCR mixture, positive controls, and 
primers for both 18S rRNA and the 3.4 kb deletion for detec-
tion in DNA extracted from blood plasma will be available 
as a Research Use Only (RUO) reagent kit in 2018. This will 
allow any third party to continue independent investigations 
using the same high-quality reagents and optimized assay 
parameters established by MDNA. The availability of the 
RUO reagent kit is intended to achieve better quality control 
and limit interlaboratory assay variability.
Statistical analysis
All samples and targets were amplified in triplicate, and 
average Cq values were calculated. The normalised 3.4 kb 
deletion value (ΔCq) was determined by relative quantifi-
cation of the 3.4 kb deletion to the 18S rRNA reference 
gene. Statistical analyses were performed using Graphpad 
Prism 5.0, (Graphpad software Inc, La Jolla, CA, USA) for 
receiver operating characteristic (ROC) curves and descrip-
tives. SPSS v.17.0 (IBM Corp., Armonk, NY, USA) was 
used for all correlations and tests of significance. The clini-
cal characteristics were summarized using count and per-
centages for the categorical data, and the mean, standard 
deviation, and range for continuous variables. The means of 
two groups were compared using the Student’s t test and the 
Mann–Whitney U test for parametric and non-parametric 
distributions, respectively. The correlation between the two 
variables was assessed with the Pearson correlation coef-
ficient (r). With respect to the presence of CS prostate can-
cer, ROC curves were constructed for the 3.4 kb mtDNA 
deletion. The area under the curve (AUC) of the ROC and 
the sensitivity and specificity at selected cut-offs were cal-
culated with 95% confidence intervals (95% CI). A p value 
< 0.05 was considered statistically significant for all tests. 
For men in the CUHT cohort, the final pathological outcome 
was based on the image-guided re-biopsy, where men with 
two negative biopsies and a negative MRI were considered 
negative controls (MRI-/Bx-). For men in the biopsy naive 
cohort, outcome was based upon grade group determined 
at prostatectomy. Men in the control group did not have 
surgical outcomes and were considered negative due to the 
absence of clinical suspicion of prostate cancer.
Results
Performance of the 3.4 kb mtDNA deletion 
in an MRI‑guided re‑biopsy population
Patient characteristics
The clinical and demographic characteristics of the 126 par-
ticipants in this cohort are summarized in Online Resource 
3. Seventy-six (60.3%) had a diagnosis of prostate cancer at 
the close of the study, with 31 (24.6%) having CS cancer. Of 
men without a diagnosis of cancer, 25 (50%) were both his-
tologically and MRI negative [MRI (−)/Bx(−)]. The mean 
(± s.d.) age for all patients, all cancer patients, all CS cancer 
patients, and all MRI(-)/Bx(−) controls was 63.77 (± 6.55), 
64.51 (± 6.18), 65.10 (± 5.90), 61.80 (± 7.57), respectively. 
The mean (± s.d.) PSA for all patients, all cancer patients, 
all CS cancer patients, and all MRI(−)/Bx(−) controls was 
6.38 (± 4.09), 6.63 (± 4.93), 5.78 (± 3.37), 6.21 (± 2.30), 
respectively. The difference between groups for age and PSA 
was not statistically significant.
3.4 kb mitochondrial DNA deletion quantity for prediction 
of CS cancers
The distribution of the 3.4 kb deletion ( ΔCq ) among MRI-/
Bx- control samples, MRI +/Bx-, GS6 and CS cancers is 
shown in Fig. 1a. The mean (± s.d.) ΔCq for control samples 
was 10.67 (± 2.429), while the mean (± s.d.) ΔCq for CS 
PCa patients was 8.16 (± 1.96). This difference was signifi-
cant at p < 0.0001. 3.4 kb deletion levels in the MRI +/ Bx- 
and grade group 1 prostate cancers were both intermediate 
between the controls and CS cancers with means of 9.61 
(± 2.75) and 8.94 (± 1.96) respectively. The nuclear DNA 
18S rRNA gene used for normalisation of the deletion quan-
tity did not vary significantly between groups (p = 0.170) 
with a mean (± s.d.) 25.5 (± 1.627) for controls and mean 
(± s.d.) 26.01 (± 0.914) for CS cancers. Neither PSA nor age 
were significantly correlated with 3.4 kb deletion quantity, 
r = − 0.052 and 0.038, respectively. The 3.4 kb deletion for 
detection of CS cancers (n = 31) produced an AUC of 0.84 
[95% CI, 0.73–0.95], p < 0.0001, when compared to levels 
detected in the control population (n = 25) (Fig. 1b). Using 
the ROC coordinates a threshold of 9.68 was selected to 
maximize the number of CS cancers detected while main-
taining acceptable specificity and corresponded to a sensi-
tivity of 87% [95% CI, 70–96%], and a specificity of 68% 
[95% CI, 47–85%].
3.4 kb mitochondrial DNA deletion for prediction of any 
cancer
The selected diagnostic threshold was applied to determine 
the accuracy with which participants diagnosed with any 
grade group prostate cancer could be distinguished from 
the control group. This yielded an AUC 0.77 [95% CI, 
0.67–0.87], p < 0.0001 with comparable specificity to the 
CS cancer at 68% [95% CI, 46–85%] but lower sensitiv-
ity at 75% [95% CI, 64–84%], meaning more grade group 
1 cancers than CS cancers are considered negative at the 
selected cut-off.
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3.4 kb mtDNA deletion and MRI
As all men in this cohort were subject to mpMRI, the accu-
racy with which the 3.4 kb deletion could predict an outcome 
of CS cancer on subsequent biopsy was compared with that 
of mpMRI using both dichotomous classification of lesion 
positive or lesion negative, as well as Likert Score. When 
an indication for biopsy was determined as the detection of 
a suspicious lesion mpMRI identified 86% of CS cancers 
with a specificity of 50%; when restricting indication for 
biopsy to a Likert Score of 4 or 5 the sensitivity decreased to 
74% with an increase in specificity to 76%. In the subgroup 
of men with a negative MRI (n = 71), defined as no suspi-
cious lesion, the 3.4 kb deletion appeared predictive of CS 
cancers [AUC 0.82, (95% CI, 0.65–0.98), p < 0.0001]. At 
the defined threshold of 9.68, the sensitivity was 88% [95% 
CI, 47–100%] and specificity was 53% [95% CI, 36–69%].
Validation of the 3.4 kb mitochondrial DNA deletion 
performance in a first biopsy cohort
Patient characteristics
The clinical and demographic characteristics for the 92 par-
ticipants of this cohort are summarized in Online Resource 
3. Sixty-three (68.5%) had an outcome of prostate cancer 
and 47 (51.1%) were CS prostate cancer. The mean (± s.d.) 
age for no cancer controls, those with any cancer, and those 
with CS cancers were 51.83 (± 4.49), 62.63 (± 5.60), and 
62.53 (± 5.86), respectively. Men in the control group were 
significantly younger than the men with a diagnosis of can-
cer (p < 0.0001). The mean (± s.d.) PSA for men with any 
cancer and those with CS cancers was 5.84 (± 2.22) and 6.01 
(± 2.14), respectively, this difference was not statistically 
significant (p = 0.69).
Fig. 1  a Distribution of nor-
malised 3.4 kb mitochondrial 
DNA deletion values for each 
clinical subgroup in the repeat 
biopsy cohort. The horizontal 
line within the box indicates the 
median, boundaries of the box 
indicate the 25th and 75th per-
centile, and the whiskers indi-
cate 10th and 90th percentile of 
the results. The “+” marked in 
the box indicates the mean. Gr 
Grp grade group. b Receiver 
operating characteristic curve 
of the 3.4 kb deletion in the 
repeat biopsy cohort. Normal-
ised 3.4 kb mtDNA deletion in 
blood plasma from men in the 
PSA ‘grey zone’ showing the 
accuracy of detection of CS (Gr 
Grp ≥ 2) cancers
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3.4 kb mitochondrial DNA deletion quantity for prediction 
of CS cancers
The distribution of the 3.4 kb deletion for each clinical 
group is shown in Fig.  2a. The mean (±  s.d.) ΔCt for 
control samples was 12.31 (± 2.43), for grade group 1, 
6.24 (± 1.29), and for CS prostate cancer patients, 4.96 
(± 1.67). This difference in deletion quantity between 
controls and CS cancer was significant at p < 0.0001. Fig-
ure 2b shows the diagnostic accuracy of the 3.4 kb dele-
tion, AUC 0.98 [95% CI, 0.94–1.02], p < 0.0001. Apply-
ing the threshold of 9.68 for discrimination of CS cancers 
corresponds to a sensitivity of 100% [95% CI, 93–100%] 
and a specificity of 90% [95% CI, 73–98%]. This threshold 
correctly classified all 47 CS cancers and 25 of the 29 con-
trols. All 16 men with grade group 1 cancers in this cohort 
were classified at this threshold as positive. The NPV and 
positive predictive value (PPV) were calculated at both 
the CS cancer incidence rate of the cohort of 62% as well 
as downward adjusted to 10%, a figure more consistent 
with the incidence observed in practice in the intended 
use population [16]. At both incidence levels, the NPV 
was 100% as all CS cancers were correctly classified with 
the deletion. The PPV was 92.1% and 44.25% for the two 
incidence levels, respectively. No significant correlation 
was observed between the 3.4 kb deletion and either PSA 
(r = − 0.098) or age (r = 0.104).
Discussion
This study is the first to report the detection of the 3.4 kb 
mitochondrial DNA deletion in plasma and establish and 
validate a useful diagnostic threshold for the accurate detec-
tion of CS prostate cancer for men in the PSA ‘grey zone’. 
Prior reports describe the detection of the 3.4 kb deletion 
in prostate tissue, serum and urine and its correlation with 
prostate cancer [5–7]. However, assay conditions defined for 
tissue were not optimal for detection in fluids, resulting in 
an unacceptable failure rate [6]. To optimize detection for 
use in blood plasma, we reduced the amplicon size for both 
the 3.4 kb deletion and the internal control, normalised input 
DNA using the internal control rather than DNA concen-
tration determined by absorbance at 260 nm, and avoided 
the use of wild-type mitochondrial DNA as it is widely 
reported to vary significantly with many other cancers as 
Fig. 2  a Distribution of the 
3.4 kb deletion in the first 
biopsy cohort. The horizontal 
line within the box indicates the 
median, boundaries of the box 
indicate the 25th and 75th per-
centile, and the whiskers indi-
cate 10th and 90th percentile of 
the results. The “+” marked in 
the box indicates the mean. Gr 
Grp grade group. b Receiver 
operating characteristic curve 
of the 3.4 kb deletion in the 
first biopsy cohort. Normalised 
3.4 kb mtDNA deletion in 
blood plasma from men in the 
PSA ‘grey zone’ showing the 
accuracy of detection of CS (Gr 
Grp ≥ 2) prostate cancers
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well as aging [17, 18] and was expected to negatively impact 
specificity for prostate cancer. With these optimizations, all 
samples in this study generated results meeting the defined 
quality requirements of the assay.
The diagnostic accuracy of the 3.4 kb deletion in plasma 
was determined first in an image-guided repeat biopsy cohort 
[AUC 0.84 (95% CI, 0.73–0.95), p < 0.0001]. A threshold 
of 9.68 ∆Cq was selected from the coordinates of the curve 
that corresponded to a sensitivity of 87% [95% CI, 70–96%], 
specificity of 68% [95% CI, 47–85%] and NPV of 97% for 
detection of CS cancers. We chose to select the threshold in 
the repeat biopsy population as the cohort was exceptionally 
well qualified with both histological and radiological con-
firmation of disease status. As the gold standard of biopsy 
is associated with a significant false negative rate [19, 20], 
selection of an optimal diagnostic threshold in a control 
group defined by histology alone can be expected to include 
30–60% or more undetected cancers [19, 20]. Thus, deter-
mination of the diagnostic threshold in the well-qualified 
image-guided repeat biopsy cohort reduced this risk [21].
The defined threshold was then tested against a second 
population of men who were biopsy naïve at the time of 
plasma collection. In this cohort, men with prostate cancer 
were diagnosed on first rather than repeat biopsy and were 
treated surgically with radical prostatectomy. Performance 
of the 3.4 kb deletion using the defined threshold was very 
high, sensitivity of 100% [95% CI, 93–100%], specificity of 
90% [95% CI, 73–98%] and NPV of 100%. Thus, the same 
diagnostic threshold was effective for the identification of 
CS cancers in either the repeat biopsy or first biopsy setting 
though more robust in the latter.
Interestingly, the mean quantity of the 3.4 kb deletion 
was significantly higher in men diagnosed on first biopsy 
compared to the repeat biopsy cohort when stratified by 
grade group, such that grade group 1 cancers detected on 
first biopsy had a significantly greater quantity of deletion 
than did grade group 1 cancers detected on repeat biopsy. 
The same finding was true for CS cancers. This may suggest 
that the increase of the 3.4 kb deletion may be associated 
not only with decreasing differentiation as seen between 
well differentiated (grade group 1) and poorly differentiated 
cancers (grade groups 2+) but perhaps tumour volume as 
tumours diagnosed on first biopsy are reportedly larger than 
those diagnosed on repeat biopsy [22, 23].
Compared to other biomarkers of prostate cancer, the 
3.4 kb deletion in a liquid biopsy format has significant 
advantages. Blood plasma is a common, non-invasive sam-
ple matrix amenable to routine testing, and a DNA analyte 
is more stable than other classes of molecules such as micro-
RNAs [24]. The performance of the biomarker, independent 
of PSA, supports its use for any man with total PSA in the 
‘grey zone’ who is being considered for biopsy, in contrast 
to PSA-derived biomarkers which may be contraindicated or 
require adjustment for men using 5-alpha-reductase inhibi-
tors [25, 26]. The standard DNA extraction, qPCR process 
and result of this single-biomarker assay is simple and cost-
effective. The assay itself is robust with a negligible failure 
rate. Finally, the accuracy with which CS prostate cancer 
within the PSA ‘grey zone’ is correctly identified or ruled 
out appears to be unsurpassed by other liquid biopsy bio-
markers such as %fPSA [AUC 0.59 (95% CI, 0.53–0.65)], 
phi [AUC 0.64 (95% CI, 0.59–0.71)], %p2PSA [AUC 0.64 
(95% CI, 0.58–0.70)] [27], and PCA3 [AUC 0.71 (95% CI, 
0.61–0.81)] [28]. (It should be noted that the lower limit 
of PSA ‘grey zone’ varied between these analyses, specifi-
cally 2 ng/ml for %fPSA, phi, and %p2PSA, and 4 ng/ml 
for PCA3).
In practice, though PSA is a good indicator of prostate 
cancer at significantly elevated levels (> 10 ng/ml) only a 
small proportion of all PSA tests performed for screening 
purposes are above this cut-off [16]. Additionally, there is 
no lower cut-off for PSA beneath which CS cancers do not 
occur—up to 15% of men with PSA less than 4 ng/ml have 
CS prostate cancer [29]. This results in a significant number 
of men in the PSA ‘grey zone’, with a PSA < 10 ng/ml, and 
a poorly qualified risk of CS prostate cancer. The diagnos-
tic uncertainty of this group results in a high proportion of 
unnecessary biopsies and thus a high NPV is of paramount 
importance for any biomarker intended to better qualify risk 
in this setting. Ideally, a negative biomarker result must cor-
relate with the absence of CS cancer nearly perfectly. The 
NPVs reported here (97% in the repeat biopsy setting, and 
100% in the first biopsy setting) appear to fulfil this require-
ment well, offering the potential to safely avoid a great many 
unnecessary biopsies while missing very few CS cancers.
As the 3.4 kb deletion performed with somewhat better 
accuracy than mpMRI in this study and was informative for 
men with a negative mpMRI result, this suggests the dele-
tion may have additional promise complementing the use of 
mpMRI, however, this requires further study.
The main limitations of this study are the availability of 
well-qualified control samples for the first biopsy cohort, the 
use of grade group classifications as a surrogate for clinically 
significant cancer and the modest sample size.
Conclusion
The 3.4 kb mitochondrial DNA deletion measured in blood 
plasma accurately predicts CS prostate cancer and corre-
lates well to both image-guided biopsy outcome in a repeat 
biopsy setting as well as prostatectomy outcome in a first 
biopsy setting for men in the PSA ‘grey zone’. As a single 
biomarker independent of PSA, the test is simple, and the 
result represents novel information with respect to risk.
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